Purine derivatives as purinergic receptor antagonists

US7452894B2 · kind B2 · utility

Assignee

• Vernalis Research Limited · GB

Inventors

• Roger John Gillespie · Wokingham, GB
• Joanne Lerpiniere · Wokingham, GB
• Claire Elizabeth Dawson · Wokingham, GB
• Suneel Gaur · Wokingham, GB
• Robert Mark Pratt · Wokingham, GB
• Gemma Caroline Stratton · Wokingham, GB
• Scott Murray Weiss · Wokingham, GB

Key dates

• Filing date: Jan 10, 2002
• Grant date: Nov 18, 2008
• Expiry date: May 4, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D473/40
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Use of a compound of formula (I) wherein R1 is selected from alkyl, aryl, alkoxy, aryloxy, 0thioalkyl, thioaryl, CN, halo, NR5R6, NR4COR5, NR4CONR5R6, NR4CO2R7 and NR4SO2R7; R2 is selected from N, O or S-containing heteroaryl groups, wherein the heteroaryl group is attached via an unsaturated carbon atom which is adjacent to one or two N, O or S-heteroatom(s), other than ortho, ortho-disubstituted heteroaryl groups; R3 is selected from H, alkyl, COR8, CONR9R10, CONR8NR9R10, CO2R11 and SO2R11; R4, R5 and R6 are independently selected from H, alkyl and aryl or where R5 and R6 are in an (NR5R6) group then R5 and R6 may be linked to form a heterocyclic ring; R7 is selected from alkyl and aryl; R8, R9 and R10 are independently selected from H, alkyl and aryl, or R9 and R10 may be linked to form a heterocyclic ring, or where R8, R9 and R10 are in a (CONR8NR9R10) group, R8 and R9 may be linked to form a heterocyclic group; and R11, is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may …